Guggenheim Maintains Buy on Enliven Therapeutics, Lowers Price Target to $78

Benzinga Newsdesk www.benzinga.com Neutral 59.8%

Neg 0% Neu 59.8% Pos 0%

Guggenheim analyst Michael Schmitz maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and lowers the price target from $80 to $78.